Soliris now approved for children, adolescents with gMG in Japan
Soliris (eculizumab), already approved in Japan for adults with generalized myasthenia gravis (gMG), has now become the first…
Articles by Marisa Wexler, MS
Soliris approved for children, ages 6-17, with generalized MG in EU
The approval of Soliris (eculizumab) in the European Union now extends to children and adolescents, ages 6 to 17,…
CHMP favors Soliris be approved in Europe to treat children with gMG
A branch of the European Medicines Agency (EMA) recommended that the approval of Soliris (eculizumab) be expanded to include…
Increased complement activation linked to antibodies against AChR
People with myasthenia gravis (MG) who are positive for antibodies against the acetylcholine receptor (AChR) — the most common…
Vyvgart for efgartigimod infusion now approved in Israel for gMG
Vyvgart (efgartigimod alfa-fcab) is now approved in Israel for the treatment of generalized myasthenia gravis (gMG), according to…
AAN 2023: Longer-term benefits seen with under-skin efgartigimod
Repeated treatment with under-the-skin efgartigimod had a consistent effect in easing symptoms of…
AAN 2023: Rozanolixizumab yields benefits across gMG patient groups
People with generalized myasthenia gravis (gMG) treated with the experimental therapy rozanolixizumab in a clinical trial generally experienced…
AAN 2023: Vyvgart for 2 years seen to ease symptoms of gMG in study
Treatment with Vyvgart (efgartigimod alfa-fcab) over two years was found to safely and effectively ease symptoms of…
AAN 2023: Zilucoplan eases symptoms in all subgroups in trial
Treatment with the experimental therapy zilucoplan eased symptoms of generalized myasthenia gravis (gMG) across different subgroups of patients…
Robot-assisted thymectomy ‘safe and feasible’ in MG: Study
Robot-assisted surgery to remove the thymus is generally safe for people with myasthenia gravis (MG), with most patients who…